Vincerx Pharma, Inc. (VINC)

NASDAQ: VINC · IEX Real-Time Price · USD
0.920
+0.011 (1.21%)
At close: Sep 22, 2023, 4:00 PM
0.912
-0.008 (-0.87%)
After-hours: Sep 22, 2023, 4:00 PM EDT
1.21%
Market Cap 19.67M
Revenue (ttm) n/a
Net Income (ttm) -56.01M
Shares Out 21.38M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,480
Open 0.925
Previous Close 0.909
Day's Range 0.875 - 0.925
52-Week Range 0.631 - 1.950
Beta 0.26
Analysts Strong Buy
Price Target 4.00 (+334.78%)
Earnings Date Nov 9, 2023

About VINC

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic m... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 41
Stock Exchange NASDAQ
Ticker Symbol VINC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for VINC stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 334.78% from the latest price.

Price Target
$4.0
(334.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...

4 days ago - GlobeNewsWire

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL

9 days ago - GlobeNewsWire

Vincerx Pharma Announces FDA Clearance of IND for VIP943

Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx' first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx's development a...

4 weeks ago - GlobeNewsWire

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash bala...

6 weeks ago - GlobeNewsWire

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class α v β 3 small molecule drug conjugate (SMDC) for the treatment of solid tumors

4 months ago - GlobeNewsWire

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

VIP924, a first-in-class CXCR5-ADC showed significant activity in patient-derived (PDX) lymphoma mouse models VIP924, a first-in-class CXCR5-ADC showed significant activity in patient-derived (PDX) ly...

5 months ago - GlobeNewsWire

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

Latest small molecule drug conjugates (SMDCs) strengthen company strategy to discover and develop paradigm-shifting drug conjugates Latest small molecule drug conjugates (SMDCs) strengthen company str...

5 months ago - GlobeNewsWire

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types VIP...

5 months ago - GlobeNewsWire

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors

6 months ago - GlobeNewsWire

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...

6 months ago - GlobeNewsWire

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...

8 months ago - GlobeNewsWire

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

VIP236 is a first-in-class α V β 3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications

10 months ago - GlobeNewsWire

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents

10 months ago - GlobeNewsWire

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Vincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) ...

10 months ago - GlobeNewsWire

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Received Orphan Drug Designation for enitociclib; continue to focus on priority indications

11 months ago - GlobeNewsWire

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...

11 months ago - GlobeNewsWire

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib

1 year ago - GlobeNewsWire

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation

1 year ago - GlobeNewsWire

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares.  The company announced a strategic update to focus on i...

1 year ago - Benzinga

Vincerx Pharma Provides Key Strategic Update

Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL

1 year ago - GlobeNewsWire

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting

1 year ago - GlobeNewsWire

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101

1 year ago - GlobeNewsWire

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through parad...

1 year ago - GlobeNewsWire

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi...

1 year ago - GlobeNewsWire